Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis - Contacts and Locations

Home

Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis

This study has been completed.

Study NCT00071838. Last updated on November 21, 2008. Information provided by National Institutes of Health Clinical Center (CC)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00071838

Locations


United States, Maryland
	National Institutes of Health Clinical Center, 9000 Rockville Pike
	Bethesda, Maryland, United States, 20892

Sponsors and Collaborators

National Institute of Neurological Disorders and Stroke (NINDS)